Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.
van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ, Trimbos JB. van Driel WJ, et al. Among authors: fleuren gj. Eur J Cancer. 1999 Jun;35(6):946-52. doi: 10.1016/s0959-8049(99)00048-9. Eur J Cancer. 1999. PMID: 10533477 Clinical Trial.
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH. van Poelgeest MI, et al. Among authors: fleuren gj. Int J Cancer. 2006 Feb 1;118(3):675-83. doi: 10.1002/ijc.21394. Int J Cancer. 2006. PMID: 16108057 Free article.
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ. Kenter GG, et al. Among authors: fleuren gj. Clin Cancer Res. 2008 Jan 1;14(1):169-77. doi: 10.1158/1078-0432.CCR-07-1881. Clin Cancer Res. 2008. PMID: 18172268 Free article. Clinical Trial.
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.
van den Hende M, van Poelgeest MI, van der Hulst JM, de Jong J, Drijfhout JW, Fleuren GJ, Valentijn AR, Wafelman AR, Slappendel GM, Melief CJ, Offringa R, van der Burg SH, Kenter GG. van den Hende M, et al. Among authors: fleuren gj. Int J Cancer. 2008 Jul 1;123(1):146-52. doi: 10.1002/ijc.23502. Int J Cancer. 2008. PMID: 18404684 Free article.
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Löwik MJ, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Melief CJ, Kenter GG, van der Burg SH. van Poelgeest MI, et al. Among authors: fleuren gj. J Transl Med. 2013 Apr 4;11:88. doi: 10.1186/1479-5876-11-88. J Transl Med. 2013. PMID: 23557172 Free PMC article. Clinical Trial.
The current status of therapeutic HPV vaccine.
van Driel WJ, Ressing ME, Brandt RM, Toes RE, Fleuren GJ, Trimbos JB, Kast WM, Melief CJ. van Driel WJ, et al. Among authors: fleuren gj. Ann Med. 1996 Dec;28(6):471-7. doi: 10.3109/07853899608999110. Ann Med. 1996. PMID: 9017105 Review.
Immunotherapeutic strategies for cervical squamous carcinoma.
van Driel WJ, Kenter GG, Fleuren GJ, Melief CJ, Trimbos BJ. van Driel WJ, et al. Among authors: fleuren gj. Hematol Oncol Clin North Am. 1999 Feb;13(1):259-73. doi: 10.1016/s0889-8588(05)70164-7. Hematol Oncol Clin North Am. 1999. PMID: 10080080 Review.
HLA and susceptibility to cervical neoplasia.
Krul EJ, Schipper RF, Schreuder GM, Fleuren GJ, Kenter GG, Melief CJ. Krul EJ, et al. Among authors: fleuren gj. Hum Immunol. 1999 Apr;60(4):337-42. doi: 10.1016/s0198-8859(98)00127-x. Hum Immunol. 1999. PMID: 10363725 Clinical Trial.
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ. Ressing ME, et al. Among authors: fleuren gj. J Immunother. 2000 Mar-Apr;23(2):255-66. doi: 10.1097/00002371-200003000-00010. J Immunother. 2000. PMID: 10746552
349 results